How Has the Pediatric Neuroblastoma Treatment Market Evolved Historically and What is its Current Size?
The pediatric neuroblastoma treatment market has seen considerable growth due to a variety of factors.
• The market for pediatric neuroblastoma treatment has seen substantial growth in the past few years. The market is set to increase from $1.85 billion in 2024 to $2.03 billion in 2025, displaying a compound annual growth rate (CAGR) of 9.4%. This notable expansion during the historic period can be credited to improvements in treatment strategies, heightened awareness and early detection, initiatives in research and development, cooperative endeavors, and enhanced survival rates.
What is the Forecasted Market Size and CAGR for the Pediatric Neuroblastoma Treatment Market Size?
The Pediatric Neuroblastoma Treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of pediatric neuroblastoma treatment is anticipated to witness robust expansion in the forthcoming years. It is envisaged to reach $2.87 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.1%.
The growth predicted in this period can be linked to numerous factors such as the rise in emerging therapies, personalized medicine, worldwide health initiatives, improved access to treatments, and the amplified role of patient advocacy and support. Key trends during this forecasted period are expected to be research collaborations, advancements in gene therapy, development of new drugs, initiation of early diagnosis and screening procedures, and enhanced patient advocacy and support.
What Key Factors and Trends Are Driving The Growth Pediatric Neuroblastoma Treatment Market?
The pediatric neuroblastoma treatment market is likely to grow due to the increasing incidence of new pediatric neuroblastoma cases. A higher prevalence of neuroblastoma has led to an increased demand for alternative treatments for pediatric neuroblastoma. Consequently, pharmaceutical companies and other stakeholders have amplified their investment in research and development, fostering innovation in the market. Additionally, with the availability of novel diagnostic technologies and screening methods, neuroblastoma can now be identified earlier, which permits for swifter treatments and improved patient outcomes. For example, an article released by the American Society of Clinical Oncology (ASCO), a US-based group of oncology professionals and physicians, estimated in March 2023 that neuroblastoma impacts approximately 700 to 800 children in the US each year. In the US, neuroblastoma accounts for 6% of all cancers in children. About 90% of neuroblastoma patients are children below the age of five. Therefore, the surge in new pediatric neuroblastoma cases is fuelling the expansion of the pediatric neuroblastoma treatment market.
What Are The Market Segments In The Pediatric Neuroblastoma Treatment Market?
The pediatric neuroblastoma treatment market covered in this report is segmented –
1) By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatment Types
2) By Risk Group: Low Risk, Intermediate Risk, High Risk
3) By End User: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Immunotherapy: Monoclonal Antibodies, Immune Checkpoint Inhibitors, CAR T-Cell Therapy
2) By Chemotherapy: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors
3) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioisotope Therapy
4) By Other Treatment Types: Surgery, Stem Cell Transplantation, Targeted Therapy
Pre-Book The Pediatric Neuroblastoma Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Pediatric Neuroblastoma Treatment Market?
Several leading enterprises in the pediatric neuroblastoma treatment market are investing in advancements like antibody technologies to amplify the effectiveness of targeted therapy and better patient prognosis. These antibody technologies comprise of different strategies and apparatus for fabricating and applying antibodies for diagnostic, therapeutic and research uses. For example, Renaissance Pharma Ltd, a clinical-stage biopharmaceutical business based in the UK, introduced Hu14.18K322A in August 2023. This targets GD2, a disialoganglioside located on the neuroblastoma cell surface. It links to these cells, bringing in immune effector cells to eliminate the tumor cells, possibly enhancing treatment results for high-risk neuroblastoma patients.
Who Are the Key Players In The Pediatric Neuroblastoma Treatment Market?
Major companies operating in the pediatric neuroblastoma treatment market include:
• United Therapeutics Corporation
• APEIRON Biologics AG
• Baxter International Inc.
• Cell Ectar Biosciences Inc.
• Pfizer Inc.
• MacroGenics Inc.
• Bayer AG
• Provectus Biopharmaceuticals Inc.
• Sartorius AG
• Y-mAbs Therapeutics Inc.
• Amgen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Clarity Pharmaceuticals
• CureSearch for Children's Cancer
• Novartis AG
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
What Are The Regional Insights Into The Pediatric Neuroblastoma Treatment Market?
North America was the largest region in the pediatric neuroblastoma treatment market in 2024. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
